ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of the management team will be virtually participating in two upcoming investor conferences. TransMedics will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020, followed by the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020.
Event: Oppenheimer Fall MedTech Summit
Format: 1x1 Meetings
Date: Thursday, November 12, 2020
Event: Canaccord Genuity Virtual MedTech & Diagnostics Forum
Format: 1X1 Meetings
Date: Thursday, November 19, 2020
As management will be participating in 1x1 meetings only, no webcasts will be available.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-participate-in-upcoming-virtual-investor-conferences-301163404.html
SOURCE TransMedics Group, Inc.
Investor Contact: Brian Johnston, 631-807-1986, Investors@transmedics.com